Check Point Inhibitors and Their Role in Immunosuppression in Sepsis
Authors:
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Critical Care Clinics
- Vol. 36 (1) , 69-88
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 86 references indexed in Scilit:
- Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsisCritical Care, 2013
- HVEM signalling at mucosal barriers provides host defence against pathogenic bacteriaNature, 2012
- Immunosuppression in Patients Who Die of Sepsis and Multiple Organ FailureJAMA, 2011
- Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infectionNature Immunology, 2011
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1International Immunology, 2010
- Unconventional ligand activation of herpesvirus entry mediator signals cell survivalProceedings of the National Academy of Sciences, 2009
- PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsisProceedings of the National Academy of Sciences, 2009
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003